Selumetinib
- Generic Name
- Selumetinib
- Brand Names
- Koselugo
- Drug Type
- Small Molecule
- Chemical Formula
- C17H15BrClFN4O3
- CAS Number
- 606143-52-6
- Unique Ingredient Identifier
- 6UH91I579U
- Background
Activation of the Raf-MEK-ERK signaling pathway is known to be implemented in several types of malignancies, thus, mitogen-activated protein kinase kinase (MEK) inhibitors such as selumetinib are important tools that can target the problematic overactivity of this pathway.
...
- Indication
Although selumetinib has been investigated for the treatment of several types of cancer, it is currently only indicated for the treatment of neurofibromatosis type 1 (NF1) in patients ≥2 years who have symptomatic, inoperable plexiform neurofibromas (PN).
- Associated Conditions
- Neurofibromatosis, type 1 (von Recklinghausen's disease)
- Associated Therapies
- -
Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)
- Conditions
- Interventions
- First Posted Date
- 2019-05-10
- Last Posted Date
- 2024-07-17
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 248
- Registration Number
- NCT03944772
- Locations
- 🇸🇪
Research Site, Stockholm, Sweden
Study of Selumetinib (MK-5618) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors (MK-5618-001)
- Conditions
- Interventions
- First Posted Date
- 2019-02-07
- Last Posted Date
- 2024-11-07
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 32
- Registration Number
- NCT03833427
- Locations
- 🇨🇦
Princess Margaret Cancer Centre ( Site 0014), Toronto, Ontario, Canada
🇺🇸City of Hope National Medical Center ( Site 0004), Duarte, California, United States
🇺🇸START Midwest ( Site 0001), Grand Rapids, Michigan, United States
Olaparib in Combination With Either Durvalumab, Selumetinib, or Capivasertib or Ceralasertib Alone in Treating Patients With Metastatic Triple Negative Breast Cancer
- First Posted Date
- 2019-01-11
- Last Posted Date
- 2024-08-13
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 132
- Registration Number
- NCT03801369
- Locations
- 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
Study of MK-8353 + Selumetinib in Advanced/Metastatic Solid Tumors (MK-8353-014)
- First Posted Date
- 2018-11-19
- Last Posted Date
- 2023-07-27
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 30
- Registration Number
- NCT03745989
- Locations
- 🇺🇸
Florida Cancer Specialists ( Site 7000), Sarasota, Florida, United States
🇺🇸Next Oncology ( Site 0001), San Antonio, Texas, United States
🇨🇦Princess Margaret Cancer Centre ( Site 0012), Toronto, Ontario, Canada
International Trial of Selumetinib in Combination With Dexamethasone for the Treatment of Acute Lymphoblastic Leukaemia
- First Posted Date
- 2018-10-15
- Last Posted Date
- 2023-05-11
- Lead Sponsor
- University of Birmingham
- Target Recruit Count
- 12
- Registration Number
- NCT03705507
- Locations
- 🇬🇧
King's College Hospital, London, United Kingdom
🇳🇱Prinses Maxima Centrum Voor Kinderoncologie, Utrecht, Netherlands
🇬🇧Birmingham Children's Hospital, Birmingham, United Kingdom
Durvalumab, Tremelimumab, and Selumetinib in Treating Participants With Recurrent or Stage IV Non-small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2018-07-10
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 40
- Registration Number
- NCT03581487
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
SARC031: MEK Inhibitor Selumetinib (AZD6244) in Combination With the mTOR Inhibitor Sirolimus for Patients With Malignant Peripheral Nerve Sheath Tumors
- Conditions
- Interventions
- First Posted Date
- 2018-02-14
- Last Posted Date
- 2023-12-26
- Target Recruit Count
- 21
- Registration Number
- NCT03433183
- Locations
- 🇺🇸
Children's National Medical Center, Washington, District of Columbia, United States
🇺🇸National Cancer Institute, Bethesda, Maryland, United States
🇺🇸Johns Hopkins University, Baltimore, Maryland, United States
A Phase 2 Study of Osimertinib in Combination With Selumetinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2018-01-05
- Last Posted Date
- 2024-08-06
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 25
- Registration Number
- NCT03392246
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Duke University, Durham, North Carolina, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
Intermittent Dosing Of Selumetinib In Childhood NF1 Associated Tumours
- Conditions
- Interventions
- First Posted Date
- 2017-10-31
- Last Posted Date
- 2024-04-04
- Target Recruit Count
- 14
- Registration Number
- NCT03326388
- Locations
- 🇬🇧
Great Ormond Street Hospital NHS Foundatin Trust, London, United Kingdom
🇬🇧Great Ormond Street Hospital for Children NHS Foundation Trust, London, United Kingdom
Selumetinib and Azacitidine in High Risk Chronic Blood Cancers
- Conditions
- Interventions
- First Posted Date
- 2017-10-31
- Last Posted Date
- 2024-01-29
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 18
- Registration Number
- NCT03326310
- Locations
- 🇺🇸
The University of Chicago, Chicago, Illinois, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.